UPSTREAM BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 61.86K shares, a 60.66% decline year-over-year.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 159.33K shares, a 324.92% increase year-over-year.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 212.03K shares, a 3019.48% increase year-over-year.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 201.37K shares.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 608.15K shares, a 1429.18% increase from fiscal 2024.
- UPSTREAM BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 39.77K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 61.86K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 634.59K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 159.33K shares 10-Q · filed 2026-05-13 | 729.99K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 212.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 608.15K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 201.37K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 402.92K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 157.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | |
| 2025-03-31 | 37.50K shares 10-Q · filed 2025-05-06 | |
| 2024-12-31 | 6.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | 39.77K shares 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |